Biktarvy
E409696
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Biktarvy canonical | 2 |
| bictegravir | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050929 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biktarvy Context triple: [Gilead Sciences, product, Biktarvy]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Biktarvy Target entity description: Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
HIV-1 treatment
ⓘ
antiretroviral medication ⓘ fixed-dose combination drug ⓘ |
| approvalYear | 2018 ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | J05AR15 ⓘ |
| belongsToTherapeuticArea |
HIV/AIDS
ⓘ
infectious diseases ⓘ |
| containsDrugClass |
integrase strand transfer inhibitor
ⓘ
nucleoside reverse transcriptase inhibitor ⓘ nucleotide reverse transcriptase inhibitor ⓘ |
| contraindicatedWith |
strong inducers of CYP3A
ⓘ
strong inducers of UGT1A1 ⓘ |
| countryOfFirstApproval |
United States
ⓘ
linked to:
United States of America
|
| developedBy |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| dosageForm | film-coated tablet ⓘ |
| hasActiveIngredient |
bictegravir
ⓘ
linked to:
Biktarvy
emtricitabine ⓘ tenofovir alafenamide ⓘ |
| hasGenericName | bictegravir/emtricitabine/tenofovir alafenamide ⓘ |
| hasSideEffect |
diarrhea
ⓘ
headache ⓘ nausea ⓘ |
| hasTradeName | Biktarvy ⓘ |
| hasWarning |
risk of acute exacerbation of hepatitis B after discontinuation
ⓘ
risk of lactic acidosis ⓘ risk of severe hepatomegaly with steatosis ⓘ |
| indicatedFor |
treatment of HIV-1 infection in adults
ⓘ
treatment of HIV-1 infection in pediatric patients ⓘ |
| intendedUse | complete regimen for HIV-1 infection ⓘ |
| isCombinationOf |
bictegravir
ⓘ
emtricitabine ⓘ
linked to:
Descovy
tenofovir alafenamide ⓘ |
| isCompleteRegimen | true ⓘ |
| isOnceDailyRegimen | true ⓘ |
| marketedBy |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| metabolismInvolves |
CYP3A
ⓘ
UGT1A1 ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| regulatoryStatus | prescription only ⓘ |
| requiresMonitoring |
hepatic function
ⓘ
renal function ⓘ |
| routeOfAdministration | oral ⓘ |
| target |
HIV-1 integrase
ⓘ
HIV-1 reverse transcriptase ⓘ |
| treats | HIV-1 infection ⓘ |
| typicalDosingFrequency | once daily ⓘ |
| usedInCombinationTherapy | no additional antiretrovirals required ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Biktarvy Description of subject: Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.